GlassScriptPhysician profile
Jama Scheidt
NPI 1013672724
$1,249.90
in general payments reported to CMS, 2019-2025
15 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.05 · 2022: $278 · 2023: $321 · 2024: $301 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $435.67 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $197.11 | 2021-2025 | |
| Novo Nordisk INC | $150.61 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $117.32 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $74.56 | 2023-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.41 | 2022-2024 | Jardiance |
| Lilly USA, LLC | $57.51 | 2023-2024 | Mounjaro, Emgality, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $33.66 | 2022 | |
| Amgen INC. | $25.68 | 2022-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $19.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.62 | 2023 | Eliquis |
| Glaxosmithkline, LLC. | $17.07 | 2025 | Trelegy Ellipta |
| Collegium Pharmaceutical, INC. | $15.46 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $14.46 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jama Scheidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.